Kelly C J, Gaudio L, Yesair D W, Schoenemann P T, Wodinsky I
Cancer Treat Rep. 1978 Jul;62(7):1025-32.
The pharmacokinetics of 5-azacytidine (5-azaCR) and tetrahydrouridine (THU) were considered in evaluating the effect of THU on chemotherapy with 5-azaCR in L1210 leukemia mice. The administration of three different dose levels of THU and 5-azaCR ip in either a 6- or 72-hour infusion gave minimal increases in therapeutic effect. At the high-dose combinations (except in the 72-hour infusion), THU appeared to enhance toxicity. Toxicity, however, occurred only after exceeding a theoretic plasma concentration for 5-azaCR of 61 microgram/ml. THU was effective in increasing the excretion of 5-azaCR by sixfold and in altering its urinary metabolites when given simultaneously with or up to 1 hour prior to 5-azaCR.
在评估四氢尿苷(THU)对L1210白血病小鼠5-氮杂胞苷(5-azaCR)化疗效果时,对5-氮杂胞苷和四氢尿苷的药代动力学进行了研究。以6小时或72小时输注的方式腹腔注射三种不同剂量水平的THU和5-azaCR,治疗效果的增加微乎其微。在高剂量组合下(72小时输注除外),THU似乎会增强毒性。然而,毒性仅在5-azaCR的理论血浆浓度超过61微克/毫升后才会出现。当与5-azaCR同时给药或在其之前1小时内给药时,THU可有效使5-azaCR的排泄增加六倍,并改变其尿液代谢产物。